Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Drug Profile

Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Alternative Names: ATR; Atripla

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb; Gilead Sciences; Merck & Co
  • Class Antiretrovirals; Benzoxazines; Nucleotides; Phosphonic acids; Purines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2017 Gilead terminates its collaboration with Bristol-Myers Squibb for Efavirenz/emtricitabine/tenofovir disoproxil fumarate in USA and Canada
  • 27 Feb 2017 Gilead Sciences has patent protection for Efavirenz/emtricitabine/tenofovir disoproxil fumarate in USA and European Union (Gilead Sciences 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top